- The U.S. FDA has accredited Roche’s (OTCQX:RHHBY) Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) as a twice a yr subcutaneous injection for multiple sclerosis.
- Ocrevus Zunovo takes solely 10 minutes to be given for relapsing and first progressive multiple sclerosis.
- Approval was primarily based on outcomes from the section III OCARINA II trial which confirmed no clinically important distinction within the ranges of Ocrevus within the bloodstream when administered subcutaneously versus intravenously. Also, the security and efficacy profile was much like the IV formulation.
Source: Seekingalpha